Foto: Hanna Olsson
| Publicerad idag 09:13

First in, first wiped out? Angels, VCs and the brutal maths of early-stage investing

Text: Cecilia Hallström | [email protected]

When a life science company takes its first outside money, it often comes from angel investors. But once venture capital enters in later rounds, the new terms can change what that early investment is worth. Part of the challenge is that “early stage” covers everything from a SEK 300,000 angel cheque to a USD 30 million Series A, with very different investors and expectations along the way. At BioStock Life Science Summit 2026, investors representing different parts of that chain met to discuss how angels and VCs could get better aligned.

Moderated by Andreas Green Rasmussen, Partner at Ugly Duckling Ventures, the panel brought together Kerstin Jakobsson, CEO of Krakesson, Tor Sander, Director at Sciety, Anders Fridlund, Board Member of Barncancerfonden Impact Invest, Mia Ekdahl, General Partner at Björk Ventures, and angel investor Jeanette Andersson of Jelifa.

With perspectives ranging from individual angels to impact investors and venture funds, the discussion set out to explore what happens to early backers when later rounds reshape the terms, and what it would take for the different parts of the chain to pull in the same direction.

See the full panel discussion “First in, first wiped out? Angels, VCs and the brutal maths of early-stage investing” below.